Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$35.00 USD
-2.22 (-5.96%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $34.76 -0.24 (-0.69%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Agios Pharmaceuticals, Inc. has a PEG ratio of 0.16 compared to the Medical - Products industry's PEG ratio of 1.56.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AGIO 35.00 -2.22(-5.96%)
Will AGIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGIO
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound?
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates
Other News for AGIO
Agios Pharmaceuticals Inc (AGIO) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ...
Agios Pharmaceuticals (AGIO) Shares Cross Below 200 DMA
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insight
Q2 2025 Agios Pharmaceuticals Inc Earnings Call Transcript
AGIO Exceeds Revenue Expectations and Prepares for Potential Approval